POPULARITY
41 episodes with axspa
24 episodes with axspa
5 episodes with axspa
12 episodes with axspa
4 episodes with axspa
5 episodes with axspa
5 episodes with axspa
5 episodes with axspa
3 episodes with axspa
5 episodes with axspa
6 episodes with axspa
5 episodes with axspa
3 episodes with axspa
5 episodes with axspa
2 episodes with axspa
2 episodes with axspa
4 episodes with axspa
3 episodes with axspa
Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress
Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
In this episode of Med Tech Gurus, we welcome Neil Klompas, Chief Executive Officer of Augurex Life Sciences. With more than two decades of experience leading companies at the intersection of diagnostics, rheumatology, and translational medicine, Neil is pioneering a new era of autoimmune biomarker discovery. Under his leadership, Augurex developed SpineStat, the world's first blood test designed to identify axial spondyloarthritis (AxSpA)āa chronic inflammatory spinal disease that affects millions yet often goes undiagnosed for nearly a decade. By leveraging the anti-14-3-3Ī· autoantibody in combination with CRP, SpineStat is helping clinicians detect disease earlier, prevent irreversible spinal damage, and even reduce opioid dependence through faster, targeted treatment. Neil shares how engaging early with regulators helped Augurex earn FDA Breakthrough Device Designation, why he believes rheumatology is poised for its "oncology moment," and how keeping his team centered on the patient journey drives innovation every day. If you're passionate about precision diagnostics, regulatory navigation, and building mission-driven teams, this episode is a masterclass in turning unmet medical need into measurable clinical impact.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Please visit answersincme.com/NHE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
Neil Klompas, President and CEO of Augurex, has a mission to improve the diagnosis of autoimmune diseases, with a primary focus on axial spondyloarthritis, a form of inflammatory back pain that is often misdiagnosed. The Augurex blood test SpineStat is designed to differentiate axSpA from mechanical back pain by identifying a specific biomarker present in axSpA. Currently, there is an average nine-year delay from the onset of symptoms to an accurate diagnosis of axSpA, causing irreversible spinal damage and years of using drugs and therapy with no benefit. Neil explains, "I think we're all familiar with back pain. Some of the NIH data and WHO data out there show that almost 28% of adult Americans live with chronic back pain, back pain lasting more than three months. It can be a real journey to figure out what the drivers are, with some patients really never getting resolution, resulting in pain management and, in some cases, even opioid pain management. But if you dive deeper into that category of back pain, there are really two broad classifications we can think about. We can think about mechanical back pain, which is due to lifting, twisting, sports injury, or maybe a car accident. But then there's this whole other category, as you indicated, called inflammatory back pain, which really has its roots in autoimmune, where the body's immune system is actually attacking itself. " Ā "Well, this is when the body's immune system attacks its peripheral joints. In inflammatory back pain, or as you said, axial spondyloarthritis, it's an autoimmune condition where the body's immune system actually attacks the spine. This can lead to pain increasing over time, new bone growth, fusion of the spinal cord, and permanent stiffness and loss of mobility. It's progressive. It keeps getting worse, and because it's an autoimmune condition. Simply stretching or swearing to take up yoga or getting a new pair of runners or doing PT or massage, while it might help with some of the symptoms, it's not going to slow down or stop the disease. The challenge with axSpA, with axial spondyloarthritis, is that while it's not really that well known or talked about in the media, it's actually more than twice as prevalent as rheumatoid arthritis, a condition which many people have heard about." #Augurex #AdvancedDiagnostics #AutoimmuneDiseases #axSpA #AxialSpondyloarthritis #BackPain augurex.com Listen to the podcast here
Neil Klompas, President and CEO of Augurex, has a mission to improve the diagnosis of autoimmune diseases, with a primary focus on axial spondyloarthritis, a form of inflammatory back pain that is often misdiagnosed. The Augurex blood test SpineStat is designed to differentiate axSpA from mechanical back pain by identifying a specific biomarker present in axSpA. Currently, there is an average nine-year delay from the onset of symptoms to an accurate diagnosis of axSpA, causing irreversible spinal damage and years of using drugs and therapy with no benefit. Neil explains, "I think we're all familiar with back pain. Some of the NIH data and WHO data out there show that almost 28% of adult Americans live with chronic back pain, back pain lasting more than three months. It can be a real journey to figure out what the drivers are, with some patients really never getting resolution, resulting in pain management and, in some cases, even opioid pain management. But if you dive deeper into that category of back pain, there are really two broad classifications we can think about. We can think about mechanical back pain, which is due to lifting, twisting, sports injury, or maybe a car accident. But then there's this whole other category, as you indicated, called inflammatory back pain, which really has its roots in autoimmune, where the body's immune system is actually attacking itself. " Ā "Well, this is when the body's immune system attacks its peripheral joints. In inflammatory back pain, or as you said, axial spondyloarthritis, it's an autoimmune condition where the body's immune system actually attacks the spine. This can lead to pain increasing over time, new bone growth, fusion of the spinal cord, and permanent stiffness and loss of mobility. It's progressive. It keeps getting worse, and because it's an autoimmune condition. Simply stretching or swearing to take up yoga or getting a new pair of runners or doing PT or massage, while it might help with some of the symptoms, it's not going to slow down or stop the disease. The challenge with axSpA, with axial spondyloarthritis, is that while it's not really that well known or talked about in the media, it's actually more than twice as prevalent as rheumatoid arthritis, a condition which many people have heard about." #Augurex #AdvancedDiagnostics #AutoimmuneDiseases #axSpA #AxialSpondyloarthritis #BackPain augurex.com Download the transcript here
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the āthe effectiveness and safety of upadacitinib with secukinumab and adalimumab' and āthe efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA'.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
From Pain to Wellness in PsAĀ Secukinumab vs Ustekinumab in PsAĀ Izokibep: still enthused about enthesitis?Ā Using Digital Apps to Modify Pain in axSpA
Revised Classification Criteria in axSpA https://www.youtube.com/watch?v=voFJrQo1ANU NSAID Addition Helps the Spine but not the Hips https://www.youtube.com/watch?v=wTKMC1MTwpE Biomarker Discovery in axSpA https://www.youtube.com/watch?v=X8Sc_3oBSVA Sexual Function in axSpA https://www.youtube.com/watch?v=r4_Nsh7e_oo Coping Strategies in axSpA https://www.youtube.com/watch?v=z9KdNuOu4nI "ROC-SpA Study" https://www.youtube.com/watch?v=kIEN39XRsSM Why do patients stay in clinical trials? https://www.youtube.com/watch?v=pVIBoN0jO2o What to do after first TNR failure in axSpA? https://www.youtube.com/watch?v=PVSyq_Y5-PE
From Pain to Wellness in PsAĀ IL-2 Therapy in SLE? MaybeĀ Sexual Function in axSpAĀ "Fact or Fiction: Trinetics Research at ACR"Ā CD1/BCMA Dual Targeting: One too many targets in SLEĀ Hydroxychloroquine Blood LevelsĀ The Great Debate: AI in RheumatologyĀ Coping Strategies in axSpAĀ "What to do After First TNR Failure in axSpA"Ā
Spondyloarthritis: The CLASSIC StudyĀ "Leftover Pain in Inflammatory Arthritis"Ā NeuroImmune Modulation in RA: Results of the RESET RA TrialĀ Change it or Keep it? TNF in Axial SpAĀ Perspectives on CAR T TherapyĀ Addressing Lupus Nephritis EarlyĀ Addressing Lupus Nephritis AggressivelyĀ CAR-T: The FutureĀ Biomarker Discovery in axSpAĀ Another Specialized Biomarker in PsAĀ Revised Classification Criteria in axSpAĀ
GDF-15: How Depression is Related to Lung Disease in RAĀ What Can we do About Chronic Pain?Ā What's the latest in PsA?Ā What to do after first TNR failure in axSpA?Ā
Off the Shelf: CAR-TĀ Combining CAR-T with CAR-Treg All in OneĀ Tapering in SELECT GCA: Steroids are the ProblemĀ Diagnostic Delays in PsA: A Radiographic PerspectiveĀ Late-Breaking Trials in axSpA and PsAĀ New Approaches to Therapy in PsAĀ PRED-SAFE: Chronic Prednisone UseĀ PsA and Brain FogĀ CAR-T Therapy: Where is it Heading?Ā
Diagnostic Delays in PsA: A Radiographic PerspectiveĀ Late-Breaking Trials in axSpA and PsAĀ New Approaches to Therapy in PsAĀ
Catching AxSpA Early: Closing the Diagnostic GapĀ Early Peripheral SpA: Is it okay to stop treatment sometimes?Ā Difficult to Manage axSpAĀ Tofacitinib in AxSpA in Developing CountriesĀ Late-Breaking Trials in axSpA and PsAĀ Durability and Safety of BimekizumabĀ Biologics Improve Sexual Function in axSpAĀ Multidimensional Pain inventory in Axial SpAĀ Spondyloarthritis: The CLASSIC StudyĀ Change it or Keep it? TNF in Axial SpAĀ "Leftover Pain in Inflammatory Arthritis"Ā
A Nose for Vasculitis: ENT Manifestations in ANCA-Associated DiseaseĀ Tofacitinib in AxSpA in Developing CountriesĀ Specialized Biomarkers in PsAĀ B Cell Depletion: Check the Lymph NodeĀ GLP-1 and SGLT-2: Treatments Too Good to Ignore?Ā Nerandomilast for ILDĀ PsA: Impact of SexĀ Cellular Biomarkers of Rheumatoid ArthritisĀ Using AI and LLMs in Qualitative DataĀ Belimumab Before or After ImmunosuppressantĀ Do Patients with Rheumatic Diseases 'Weather' the Storm?Ā AI in Fellow Recruitment: A New Dawn in Medical Education?Ā
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
Listen or watch along as we dive into updates on axial spondyloarthritis (axSpA) treatments and 'The 2025 British Society for Rheumatology guidelineĀ Ā for treatment ofĀ Ā axial Spondyloarthritis with biologic and targeted synthetic DMARDs'.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks withĀ Professor Raj Sengupta, Consultant rheumatologistĀ Ā and Lead Consultant for Axial SpondyloarthritisĀ at the RNHRD, RUH Bath about changes to axSpAĀ treatmentsĀ since our first series in 2020. Useful Links:BSR Guidelineā National Axial Spondyloarthritis Societyā InhealthcareĀ Ā Connect further with us:Have questions or thoughts aboutĀ our information Podcast library?Ā Interested in joining BIRDs patient research panel?Ā Email Mel atĀ Ā ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit theā ā ā ā ā Ā ā ā ā ā ā ā ā BIRD websiteĀ ā ā ā ā ā ā ā ā ā ā ā ā Ā to sign up for news.
Listen or watch along as we dive into updates on axial spondyloarthritis (axSpA) treatments and 'The 2025 British Society for Rheumatology guidelineĀ Ā for treatment ofĀ Ā axial Spondyloarthritis with biologic and targeted synthetic DMARDs'.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks withĀ Professor Raj Sengupta, Consultant rheumatologistĀ Ā and Lead Consultant for Axial SpondyloarthritisĀ at the RNHRD, RUH Bath about changes to axSpAĀ treatmentsĀ since our first series in 2020. Useful Links:ā BSR Guidelineā ā ā National Axial Spondyloarthritis Societyā ā ā InhealthcareĀ Ā ā Connect further with us:Have questions or thoughts aboutĀ our information Podcast library?Ā Interested in joining BIRDs patient research panel?Ā Email Mel atĀ Ā ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit theā ā ā ā ā ā Ā ā ā ā ā ā ā ā BIRD websiteĀ ā ā ā ā ā ā ā ā ā ā ā ā ā Ā to sign up for news.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the realāworld comparison of clinical effectiveness of UPA, TNF inhibitors or ILā17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Listen or watch along as we dive into the changing landscape of axial spondyloarthritis (axSpA) diagnosis.In this episode, podcast host Mel Brooke, BIRDs Patient and Public Engagement Programme talks withĀ Dr Tom Williams, Consultant rheumatologist and Education Lead at the RNHRD, RUH Bath about changes to the axSpA diagnosis process since our first series in 2020. From persistent delays and the different experiences of women, to new tools like the NASS Playbook, PRIMIS pop-up, and Symptom Checker, we look at what's helping clinicians and patients. We also touch on non-radiographic axSpA, the growing role of MRI, blood markers, and how to approach cases that aren't clear-cut ā before rounding off with some patient questions.Ā Useful Links:National Axial Spondyloarthritis SocietyRoyal National Hospital for Rheumatic Diseases, RUH BathConnect further with us:Have questions or thoughts aboutĀ our information Podcast library?Ā Interested in joining BIRDs patient research panel?Ā Email Mel atĀ Ā ppe@birdbath.org.ukBe sure to subscribe, rate, and review the podcast to help us continue sharing information that matters!Thank you to all our sponsors for helping us to bring you information that supports you and helps to increase your knowledge of rheumatic diseases.Please visit theā ā ā ā Ā ā ā ā ā ā ā ā BIRD websiteĀ ā ā ā ā ā ā ā ā ā ā ā Ā to sign up for news.
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the āthe influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA' and āthe incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab'.
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.
Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.
Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they guide you through what they are most looking forward to in RA, PsA, and axSpA at EULAR 2025, so that you can better plan your time at what will be a busy and exciting congress.
In this episode, we examine the evaluation of pain in patients with chronic inflammatory arthritis, with particular attention to spondyloarthritis and its clinical overlap with fibromyalgia. We explore why some patients continue to report persistent pain despite well-controlled inflammation, and the importance of distinguishing between active inflammatory disease and centralized pain syndromes such as fibromyalgia. Join us as we unpack the diagnostic nuances that can significantly impact patient care.Ā
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.
In this episode, we're joined by Dr. Atul Deodhar, a leading expert in the field of Axial Spondyloarthritis (AxSpA). Dr. Deodhar shares insights from his groundbreaking research on the pathophysiology, diagnosis, and management of AxSpA, particularly focusing on the efficacy and safety of IV secukinumab. We dive deep into his study, INVIGORATE-1, exploring the methods behind it, including the use of Interactive Response Technology, and the primary and secondary endpoints that shed light on this treatment's impact. We also discuss the latest data on patient preferences for subcutaneous versus intravenous immunomodulators and the implications of these findings. Tune in for an informative and engaging conversation that blends cutting-edge science with thoughtful reflections on patient care.Ā
In this episode, we dive into the cutting-edge advancements presented by Dr. Christopher T. Ritchlin at Convergence 2024, where he shed light on the promising research set to transform the field of rheumatology. Join us as we break down key insights from one of the field's leading experts, exploring the future of precision medicine, the role of TRBV9 cells in axSpA, the impact of sex differences on PsA, and the potential of urinary biomarkers in Lupus Nephritis. Tune in for a fascinating discussion on what's next in rheumatology.Ā
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideationĀ Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:https://bit.ly/4gkTzSv
Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideationĀ Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:Ā bit.ly/4gkTzSv
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.
In this episode, we explore the findings of a groundbreaking study analyzing opioid treatment trends for adults with and without systemic autoimmune and inflammatory rheumatic diseases (SARDs) from 2006 to 2019. The study, based on national data from the United States, sheds light on how individuals with conditions like rheumatoid arthritis, lupus, and ankylosing spondylitis are impacted by opioid use compared to the general population.Ā
A New ACR Anti IL-17 on Entheseal Biopsy in PsA axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure Best Things I Saw Today in PsA Cycling vs Switching after TNFi Failure in axSpA Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Sonelokimab in PsA: Phase 2 Data Treating SpA
A New ACR Apremilast Benefits and Risks in PsA Best Things I Saw Today in PsA Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Biologic Monotherapy vs Combination with cDMARDs in PsA Do TNFis and JAKis Prevent Cancer!? Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Potential Impact of Weight Loss Drugs in Rheumatic Diseases Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis PsA Potpourri PsA Ultrasound Updates PsA: Impact of Sex Sex Differences in Psoriatic Arthritis The Psoriatic March: PsA before PsO Apremilast in PsA: Results from Mosaic Trial Anti IL-17 on Entheseal Biopsy in PsA
A New ACR Assessing ASAS Criteria: CLASSIC Study Results Assessment and management of axSpA Assessment of axSpA Carotid Doppler Ultrasound Screening in Axial SpA Cycling vs Switching after TNFi Failure in axSpA Defining Difficult to Manage axSpA Difficult to manage AxSpA DISH in SpA Gender Differences in AxSpA Highlights in axSpA Hot Topics in axSpA Long-term Safety Profile of Bimekizumab in axSpA and PsA Machine Learning for Predicting Flares in axSpA Precision Immunotherapy in Axial SpA PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Treating SpA What is a Positive MRI in Spondyloarthritis? axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure
Control RA, Build Stronger Bones:Dr. Jiha Lee talks with Dr. Rachel ElamĀ Hold or continue JAKi and IL-17 when receiving COVID boosters?:Dr. Bella Mehta Long-term Safety Profile of Bimekizumab in axSpA and PsA:Dr. Philip Mease Navigating Rheumatology Care in Humanitarian Crisis Settings:Dr. Antoni Chan talks with Dr. Martha Dhzhus RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?:Dr. Eric DeinĀ Sex Differences in Psoriatic Arthritis:Dr. Catherine Bakewell Single v Double Lung Transplants for Disease-related ILD:Dr. Eric Dein talks with Dr. Harry Hurley Sonelokimab in PsA: Phase 2 Data:Dr. Philip Mease Treating SpA:Dr. Marina Magrey
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab
© 2020-2026 Ivy Podcast Discovery LLC
